San Diego, California Sep 9, 2024 (Issuewire.com) - Jaan Biotherapeutics, a company developing microRNA targeting treatments for heart disease, the leading cause of death of both women and men in the United States of America, announced today that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).

Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and Minority- Serving Institutions, with the ultimate aim of delivering scalable healthcare outcomes for all Americans. Dr. Brar, the Chief Executive Officer and minority founder stated "We are extremely thrilled and honored to be selected as a spoke for the investor Catalyst Hub. The company was formed over nine years ago with our primary mission to develop treatments for ischemic heart disease, by targeting noncoding RNAs known as microRNAs to repair and regenerate heart muscle within the damaged organ. Jaans mission aligns with ARPA-H's mission-and this is an amazing opportunity for the company to collaborate and expedite the development of our potential treatments to all those that need it."

Jaan Biotherapeutics joins a dynamic nationwide network of organizations aligned to ARPA-Hs overarching mission to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. Investor Catalyst Hub spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.

Our spoke network embodies a rich and representative range of perspectives and expertise, said Mark Marino, Vice President of Growth Strategy and Development for VentureWell and Project Director for the Investor Catalyst Hub. Our spokes comprise a diverse network that will be instrumental in ensuring that equitable health solutions reach communities across every state and tribal nation.

As an Investor Catalyst Hub spoke, Jaan Biotherapeutics gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. Spoke membership also offers opportunities to provide input on ARPA-H challenge areas and priorities, along with access to valuable networking opportunities and a robust resource library.

The spoke network will continue to grow as the Investor Catalyst Hub expands its efforts, with applications being selected on a rolling basis. Interested organizations can visit https://investorcatalysthub.org/ to learn more or submit a membership application.